Clinical trials: Cerebral Disorder
Japanese Encephalitis Virus Disease
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
This is a 2-Stage, Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)
- Trial name
- NCT06680128
- Testing
- GBP560-A, GBP560-B, IXIARO
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
- Trial name
- NCT02880956
- Testing
- ABBV-8E12
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Friedreich Ataxia, Cardiomyopathy
A Study of ASP2016 in Adults Who Have Heart Disease Associated With Friedreich Ataxia
Friedreich Ataxia is a rare condition that causes damage to the nervous system and muscles. People with Friedreich Ataxia have difficulty walking, lose sensation in their arms and legs, and have slurred speech.
- Trial name
- NCT06483802
- Testing
- ASP2016, Prednisolone
- Sponsor
- Astellas Gene Therapies
Cerebral Atherosclerosis
Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis
The purpose of this study is to obtain additional data on efficacy and safety of Divaza for adjustment of oxidative disorders in patients with cerebral atherosclerosis.
- Trial name
- NCT03485495
- Testing
- Divaza
- Where
- 10 sites in Russia
- Volunteers
- 124 people
- Sponsor
- Materia Medica Holding
Epilepsies, Partial
Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)
This investigation aims to understand the following issues in pediatric patients, as well as to assess the need of a special investigation and a post-marketing clinical study: The frequency of treatment related adverse events.
- Trial name
- NCT01441401
- Testing
- gabapentin
- Volunteers
- 82 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Parkinson Disease
Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients with motor fluctuations.
- Trial name
- NCT04191577
- Testing
- CVN424 Low Dose, CVN424 High Dose
- Where
- 21 sites in United States
- Volunteers
- 136 people
- Sponsor
- Cerevance Beta, Inc.
Parkinson's Disease
A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)
This study is to evaluate the efficacy of a range of preladenant doses compared with placebo in participants with moderate to severe Parkinson's disease (PD) experiencing motor fluctuations and receiving a stable dose of levodopa…
- Trial name
- NCT01294800
- Testing
- Preladenant
- Volunteers
- 450 people
- Sponsor
- Merck Sharp & Dohme LLC
Ataxia Telangiectasia Louis-Bar, Ataxia Telangiectasia in Children
MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia
Ataxia Telangiectasia (A-T) is an autosomal recessively inherited neurodegenerative disorder that also has dramatic effects on the immune and endocrine systems.
- Conditions
- Ataxia Telangiectasia Louis-Bar, Ataxia Telangiectasia in Children, Ataxia Telangiectasia
- Trial name
- NCT04887311
- Testing
- MBM-01
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Matrix Biomed, Inc.
Growth Hormone Deficiency (GHD)
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
A six month study of ACP-001, a long-acting growth hormone product, versus standard human growth hormone therapy. ACP-001 will be given once-a-week, standard human growth hormone (hGH) will be given on a daily basis.
- Trial name
- NCT01947907
- Testing
- ACP-001, Human Growth Hormone
- Where
- 36 sites in Belarus, Bulgaria and 12 more
- Volunteers
- 53 people
- Sponsor
- Ascendis Pharma A/S
Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
This study aims to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels.
- Conditions
- Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack), Unstable Angina, Angina
- Trial name
- PALACE (NCT04097912)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Hepatic Encephalopathy, Cirrhosis
The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
The purpose of the study is to evaluate if rifaximin alone or rifaximin plus lactulose delays the onset of hepatic encephalopathy (HE) in participants with cirrhosis who have had a previous episode of HE.
- Trial name
- NCT01842581
- Testing
- Rifaximin, Lactulose
- Where
- 43 sites in United States
- Volunteers
- 222 people
- Sponsor
- Bausch Health Americas, Inc.
Alzheimer Disease, Healthy Volunteers
Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
The purpose of this study was to assess the safety, tolerability, and pharmacokinetic (PK) of TAK-071 when administered as single rising dose (SRD) and multiple rising dose (MRD) orally in healthy participants and participants…
- Trial name
- NCT02769065
- Testing
- TAK-071, Donepezil
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Takeda
Migraine
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
- Trial name
- UBR Prodrome (NCT04492020)
- Testing
- Ubrogepant 100 mg
- Where
- 73 sites in United States
- Volunteers
- 518 people
- Sponsor
- AbbVie
Glioma, Primary Brain Tumor
MRI-based Computer Aided Diagnosis Software (V1) for Glioma
The goal of this multi-center clinical trial is to evaluate the effectiveness of MRI-based computer-aided diagnosis software (V1) for glioma segmentation, gene prediction, and tumor grading.
- Trial name
- NCT05739500
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Mingge LLC
Japanese Encephalitis
Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440
The objective is to investigate the immunogenicity of the Japanese Encephalitis vaccine IC51 (JE-PIV) single and concomitant with HAVRIX® 1440
- Trial name
- NCT00596271
- Testing
- IC51, HAVRIX
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Alzheimer Disease
Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD
The purpose of this study is to study the effect of monthly dosing with a single dose of Lu AF20513, with and without booster vaccine, on antibody response.
- Trial name
- NCT03819699
- Testing
- Lu AF20513, booster vaccine
- Where
- 3 sites in Finland, Sweden
- Volunteers
- 3 people
- Sponsor
- H. Lundbeck A/S
Fabry's Disease
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume.
- Trial name
- SHORTEN (NCT06019728)
- Testing
- AGALSIDASE BETA (GZ419828), Acetaminophen, Diphenhydramine
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sanofi
Acute Ischemic Stroke
Acute Ischemic Stroke Interventional Study
To assess safety of single IV (bolus + infusion) doses of ACT017 in patients with an acute ischemic stroke in addition to best emergency standard of care (including fibrinolysis by rtPA with or without added thrombectomy), with a…
- Trial name
- ACTIMIS (NCT03803007)
- Testing
- Intravenous ACT017 1000 mg
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Acticor Biotech
Alzheimer's Disease
EEG/ERP Longitudinal Study in Alzheimer's Disease (AD)
In a previous study, NCT00582127, two age-matched cohorts, one clinically diagnosed with mild Alzheimer's disease and the other healthy controls, were tested with a hand-held EEG/ERP system to determine if the cohorts could be…
- Trial name
- NCT02769234
- Testing
- ERP/EEG test, Psychometric testing
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Neuronetrix, Inc.
Glycogen Storage Disease Type II, Glycogenosis 2
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease
Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA).
- Trial name
- NCT00074932
- Testing
- Myozyme
- Where
- 8 sites in United States
- Volunteers
- 9 people
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.